中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 9
Sep.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(9): 1908-1915

Pyroptosis： A new bridge connecting gut microbiota and liver diseases

DOI: 10.12449/JCH240930
  • 1.

    The First Clinical Medical College of Henan University of Chinese Medicine，Zhengzhou 450000，China

  • 2.

    Spleen，Stomach and Hepatobiliary Department，The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450000，China

Research funding:

Natural Science Foundation of Henan Province (222300420490);

Joint Fund for Science and Technology Research and Development Plan of Henan Province (222301420069);

Construction Project of Traditional Chinese Medicine Discipline as a Key Discipline with Characteristics in Henan Province (STG-ZYXKY-2020017)

More Information
  • Corresponding author: LIU Guangwei， liuguangwei1975@163.com （ORCID： 0000-0002-6641-1625）
  • Received Date: 2023-10-27
  • Accepted Date: 2023-11-29
  • Published Date: 2024-09-25
    Abstract
  • Since the proposal of the concept of the gut-liver axis， a large number of studies have focused on exploring the connection between gut microbiota and liver disease； however， the idea of using pyroptosis as a hub to explore the intrinsic mechanism of gut-liver crosstalk is still in its infancy. This article mainly describes the process by which gut microbiota dysbiosis affects the integrity of mucosal barrier and bile acid metabolism， induces pyroptosis， and thereby affects the development and progression of liver diseases， and it also concludes that gut microbiota dysbiosis affects liver diseases by inducing NLRP3/AIM2/Caspase-1-dependent， Caspase-4/11/GSDMD-dependent， and Caspase-3/GSDME-dependent pyroptosis. In summary， this study aims to provide new ideas and targets for the future diagnosis and treatment of liver diseases by establishing the connection between pyroptosis and intestinal-liver immune crosstalk.

     

    • FullText(HTML)
  • loading
    • References(67)
  • [1]
    de VOS WM, TILG H, van HUL M, et al. Gut microbiome and health: Mechanistic insights[J]. Gut, 2022, 71( 5): 1020- 1032. DOI: 10.1136/gutjnl-2021-326789.
    [2]
    PABST O, HORNEF MW, SCHAAP FG, et al. Gut-liver axis: Barriers and functional circuits[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 7): 447- 461. DOI: 10.1038/s41575-023-00771-6.
    [3]
    KNORR J, WREE A, FELDSTEIN AE. Pyroptosis in steatohepatitis and liver diseases[J]. J Mol Biol, 2022, 434( 4): 167271. DOI: 10.1016/j.jmb.2021.167271.
    [4]
    GIUFFRÈ M, CAMPIGOTTO M, CAMPISCIANO G, et al. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318( 5): G889- G906. DOI: 10.1152/ajpgi.00161.2019.
    [5]
    KNORR J, WREE A, FELDSTEIN AE. Pyroptosis in steatohepatitis and liver diseases[J] Mol Biol, 2022, 434( 4): 167271. DOI: 10.1016/j.jmb.2021.167271.
    [6]
    CHOPYK DM, GRAKOUI A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders[J]. Gastroenterology, 2020, 159( 3): 849- 863. DOI: 10.1053/j.gastro.2020.04.077.
    [7]
    ECKBURG PB, BIK EM, BERNSTEIN CN, et al. Diversity of the human intestinal microbial flora[J]. Science, 2005, 308( 5728): 1635- 1638. DOI: 10.1126/science.1110591.
    [8]
    MOWAT AM, AGACE WW. Regional specialization within the intestinal immune system[J]. Nat Rev Immunol, 2014, 14( 10): 667- 685. DOI: 10.1038/nri3738.
    [9]
    BEL S, PENDSE M, WANG YH, et al. Paneth cells secrete lysozyme via secretory autophagy during bacterial infection of the intestine[J]. Science, 2017, 357( 6355): 1047- 1052. DOI: 10.1126/science.aal4677.
    [10]
    MÖRBE UM, JØRGENSEN PB, FENTON TM, et al. Human gut-associated lymphoid tissues(GALT); diversity, structure, and function[J]. Mucosal Immunol, 2021, 14( 4): 793- 802. DOI: 10.1038/s41385-021-00389-4.
    [11]
    YANG WJ, CONG YZ. Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases[J]. Cell Mol Immunol, 2021, 18( 4): 866- 877. DOI: 10.1038/s41423-021-00661-4.
    [12]
    ANDERSON MJ, DEN HARTIGH AB, FINK SL. Molecular mechanisms of pyroptosis[J]. Methods Mol Biol, 2023, 2641: 1- 16. DOI: 10.1007/978-1-0716-3040-2_1.
    [13]
    SANTOS JC, DICK MS, LAGRANGE B, et al. LPS targets host guanylate-binding proteins to the bacterial outer membrane for non-canonical inflammasome activation[J]. EMBO J, 2018, 37( 6): e98089. DOI: 10.15252/embj.201798089.
    [14]
    WANG JF, DONG R, ZHENG S. Roles of the inflammasome in the gut-liver axis(Review)[J]. Mol Med Rep, 2019, 19( 1): 3- 14. DOI: 10.3892/mmr.2018.9679.
    [15]
    FERNANDES-ALNEMRI T, WU J, YU JW, et al. The pyroptosome: A supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation[J]. Cell Death Differ, 2007, 14( 9): 1590- 1604. DOI: 10.1038/sj.cdd.4402194.
    [16]
    SHAO F. Gasdermins: Making pores for pyroptosis[J]. Nat Rev Immunol, 2021, 21( 10): 620- 621. DOI: 10.1038/s41577-021-00602-2.
    [17]
    CHEN KW, DEMARCO B, BROZ P. Pannexin-1 promotes NLRP3 activation during apoptosis but is dispensable for canonical or noncanonical inflammasome activation[J]. Eur J Immunol, 2020, 50( 2): 170- 177. DOI: 10.1002/eji.201948254.
    [18]
    HUANG XL, FENG Y, XIONG GQ, et al. Caspase-11, a specific sensor for intracellular lipopolysaccharide recognition, mediates the non-canonical inflammatory pathway of pyroptosis[J]. Cell Biosci, 2019, 9: 31. DOI: 10.1186/s13578-019-0292-0.
    [19]
    WANG YP, GAO WQ, SHI XY, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin[J]. Nature, 2017, 547( 7661): 99- 103. DOI: 10.1038/nature22393.
    [20]
    ZHOU ZW, HE HB, WANG K, et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells[J]. Science, 2020, 368( 6494): eaaz7548. DOI: 10.1126/science.aaz7548.
    [21]
    BARNETT KC, LI SR, LIANG KX, et al. A 360° view of the inflammasome: Mechanisms of activation, cell death, and diseases[J]. Cell, 2023, 186( 11): 2288- 2312. DOI: 10.1016/j.cell.2023.04.025.
    [22]
    ZHANG YW, YANG WL, LI WG, et al. NLRP3 inflammasome: Checkpoint connecting innate and adaptive immunity in autoimmune diseases[J]. Front Immunol, 2021, 12: 732933. DOI: 10.3389/fimmu.2021.732933.
    [23]
    MARTENS EC, NEUMANN M, DESAI MS. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier[J]. Nat Rev Microbiol, 2018, 16( 8): 457- 470. DOI: 10.1038/s41579-018-0036-x.
    [24]
    XUE SG, XUE Y, DOU DB, et al. Kui Jie Tong ameliorates ulcerative colitis by regulating gut microbiota and NLRP3/caspase-1 classical pyroptosis signaling pathway[J]. Dis Markers, 2022, 2022: 2782112. DOI: 10.1155/2022/2782112.
    [25]
    SZABO G, CSAK T. Inflammasomes in liver diseases[J]. J Hepatol, 2012, 57( 3): 642- 654. DOI: 10.1016/j.jhep.2012.03.035.
    [26]
    HAO HP, CAO LJ, JIANG CT, et al. Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis[J]. Cell Metab, 2017, 25( 4): 856- 867.e5. DOI: 10.1016/j.cmet.2017.03.007.
    [27]
    PERINO A, SCHOONJANS K. Metabolic messengers: Bile acids[J]. Nat Metab, 2022, 4( 4): 416- 423. DOI: 10.1038/s42255-022-00559-z.
    [28]
    HAN CY, RHO HS, KIM A, et al. FXR inhibits endoplasmic reticulum stress-induced NLRP3 inflammasome in hepatocytes and ameliorates liver injury[J]. Cell Rep, 2018, 24( 11): 2985- 2999. DOI: 10.1016/j.celrep.2018.07.068.
    [29]
    CHEN Y, LE TH, DU QM, et al. Genistein protects against DSS-induced colitis by inhibiting NLRP3 inflammasome via TGR5-cAMP signaling[J]. Int Immunopharmacol, 2019, 71: 144- 154. DOI: 10.1016/j.intimp.2019.01.021.
    [30]
    HANG SY, PAIK D, YAO LN, et al. Bile acid metabolites control TH17 and Treg cell differentiation[J]. Nature, 2019, 576( 7785): 143- 148. DOI: 10.1038/s41586-019-1785-z.
    [31]
    HUANG FJ, ZHENG XJ, MA XH, et al. Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism[J]. Nat Commun, 2019, 10( 1): 4971. DOI: 10.1038/s41467-019-12896-x.
    [32]
    MANNS MP, LOHSE AW, VERGANI D. Autoimmune hepatitis-update 2015[J]. J Hepatol, 2015, 62( 1): S100- S111. DOI: 10.1016/j.jhep.2015.03.005.
    [33]
    LIU QY, HE W, TANG RQ, et al. Intestinal homeostasis in autoimmune liver diseases[J]. Chin Med J, 2022, 135( 14): 1642- 1652. DOI: 10.1097/CM9.0000000000002291.
    [34]
    LI LP, KANG YB. The gut microbiome and autoimmune hepatitis: Implications for early diagnostic biomarkers and novel therapies[J]. Mol Nutr Food Res, 2023, 67( 24): e2300043. DOI: 10.1002/mnfr.202300043.
    [35]
    CHEN JN, WEI YF, HE JQ, et al. Natural killer T cells play a necessary role in modulating of immune-mediated liver injury by gut microbiota[J]. Sci Rep, 2014, 4: 7259. DOI: 10.1038/srep07259.
    [36]
    KANG YB, KUANG XY, YAN H, et al. A novel synbiotic alleviates autoimmune hepatitis by modulating the gut microbiota-liver axis and inhibiting the hepatic TLR4/NF-κB/NLRP3 signaling pathway[J]. mSystems, 2023, 8( 2): e0112722. DOI: 10.1128/msystems.01127-22.
    [37]
    WANG H, WANG GD, LIANG YJ, et al. Redox regulation of hepatic NLRP3 inflammasome activation and immune dysregulation in trichloroethene-mediated autoimmunity[J]. Free Radic Biol Med, 2019, 143: 223- 231. DOI: 10.1016/j.freeradbiomed.2019.08.014.
    [38]
    SEITZ HK, BATALLER R, CORTEZ-PINTO H, et al. Alcoholic liver disease[J]. Nat Rev Dis Primers, 2018, 4( 1): 16. DOI: 10.1038/s41572-018-0014-7.
    [39]
    CHO YE, SONG BJ. Pomegranate prevents binge alcohol-induced gut leakiness and hepatic inflammation by suppressing oxidative and nitrative stress[J]. Redox Biol, 2018, 18: 266- 278. DOI: 10.1016/j.redox.2018.07.012.
    [40]
    PETRASEK J, IRACHETA-VELLVE A, SAHA B, et al. Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells in alcoholic liver disease[J]. J Leukoc Biol, 2015, 98( 2): 249- 256. DOI: 10.1189/jlb.3AB1214-590R.
    [41]
    WU S, WEN F, ZHONG XB, et al. Astragaloside IV ameliorate acute alcohol-induced liver injury in mice via modulating gut microbiota and regulating NLRP3/caspase-1 signaling pathway[J]. Ann Med, 2023, 55( 1): 2216942. DOI: 10.1080/07853890.2023.2216942.
    [42]
    KHANOVA E, WU R, WANG W, et al. Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients[J]. Hepatology, 2018, 67( 5): 1737- 1753. DOI: 10.1002/hep.29645.
    [43]
    CALIGIURI A, GENTILINI A, MARRA F. Molecular pathogenesis of NASH[J]. Int J Mol Sci, 2016, 17( 9): 1575. DOI: 10.3390/ijms17091575.
    [44]
    MUSSO G, CASSADER M, GAMBINO R. Non-alcoholic steatohepatitis: Emerging molecular targets and therapeutic strategies[J]. Nat Rev Drug Discov, 2016, 15( 4): 249- 274. DOI: 10.1038/nrd.2015.3.
    [45]
    BASHIARDES S, SHAPIRO H, ROZIN S, et al. Non-alcoholic fatty liver and the gut microbiota[J]. Mol Metab, 2016, 5( 9): 782- 794. DOI: 10.1016/j.molmet.2016.06.003.
    [46]
    TIAN GG, WANG W, XIA ER, et al. Dendrobium officinale alleviates high-fat diet-induced nonalcoholic steatohepatitis by modulating gut microbiota[J]. Front Cell Infect Microbiol, 2023, 13: 1078447. DOI: 10.3389/fcimb.2023.1078447.
    [47]
    CSAK T, GANZ M, PESPISA J, et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells[J]. Hepatology, 2011, 54( 1): 133- 144. DOI: 10.1002/hep.24341.
    [48]
    ZHU YW, ZHAO H, LU J, et al. Caspase-11-mediated hepatocytic pyroptosis promotes the progression of nonalcoholic steatohepatitis[J]. Cell Mol Gastroenterol Hepatol, 2021, 12( 2): 653- 664. DOI: 10.1016/j.jcmgh.2021.04.009.
    [49]
    YANG JJ, WANG DW, LI YC, et al. Metabolomics in viral hepatitis: Advances and review[J]. Front Cell Infect Microbiol, 2023, 13: 1189417. DOI: 10.3389/fcimb.2023.1189417.
    [50]
    SEHGAL R, BEDI O, TREHANPATI N. Role of microbiota in pathogenesis and management of viral hepatitis[J]. Front Cell Infect Microbiol, 2020, 10: 341. DOI: 10.3389/fcimb.2020.00341.
    [51]
    LU YX, HE CZ, WANG YX, et al. Effect of entecavir on the intestinal microflora in patients with chronic hepatitis B: A controlled cross-sectional and longitudinal real-world study[J]. Infect Dis Ther, 2021, 10( 1): 241- 252. DOI: 10.1007/s40121-020-00355-w.
    [52]
    INOUE T, NAKAYAMA J, MORIYA K, et al. Gut dysbiosis associated with hepatitis C virus infection[J]. Clin Infect Dis, 2018, 67( 6): 869- 877. DOI: 10.1093/cid/ciy205.
    [53]
    NEGASH AA, RAMOS HJ, CROCHET N, et al. IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease[J]. PLoS Pathog, 2013, 9( 4): e1003330. DOI: 10.1371/journal.ppat.1003330.
    [54]
    YU X, LAN PX, HOU XB, et al. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production[J]. J Hepatol, 2017, 66( 4): 693- 702. DOI: 10.1016/j.jhep.2016.12.018.
    [55]
    XIE WH, DING J, XIE XX, et al. Hepatitis B virus X protein promotes liver cell pyroptosis under oxidative stress through NLRP3 inflammasome activation[J]. Inflamm Res, 2020, 69( 7): 683- 696. DOI: 10.1007/s00011-020-01351-z.
    [56]
    PAN XF, XU HX, ZHENG CL, et al. Human hepatocytes express absent in melanoma 2 and respond to hepatitis B virus with interleukin-18 expression[J]. Virus Genes, 2016, 52( 4): 445- 452. DOI: 10.1007/s11262-016-1327-9.
    [57]
    HAN Y, CHEN Z, HOU R, et al. Expression of AIM2 is correlated with increased inflammation in chronic hepatitis B patients[J]. Virol J, 2015, 12: 129. DOI: 10.1186/s12985-015-0360-y.
    [58]
    HO DWH, LO RCL, CHAN LK, et al. Molecular pathogenesis of hepatocellular carcinoma[J]. Liver Cancer, 2016, 5( 4): 290- 302. DOI: 10.1159/000449340.
    [59]
    LUO WY, GUO SQ, ZHOU Y, et al. Hepatocellular carcinoma: How the gut microbiota contributes to pathogenesis, diagnosis, and therapy[J]. Front Microbiol, 2022, 13: 873160. DOI: 10.3389/fmicb.2022.873160.
    [60]
    BI CC, XIAO GQ, LIU CY, et al. Molecular immune mechanism of intestinal microbiota and their metabolites in the occurrence and development of liver cancer[J]. Front Cell Dev Biol, 2021, 9: 702414. DOI: 10.3389/fcell.2021.702414.
    [61]
    ZHAO HJ, ZHANG YM, ZHANG YT, et al. The role of NLRP3 inflammasome in hepatocellular carcinoma[J]. Front Pharmacol, 2023, 14: 1150325. DOI: 10.3389/fphar.2023.1150325.
    [62]
    LIU BY, ZHOU ZW, JIN Y, et al. Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma[J]. J Immunother Cancer, 2022, 10( 1): e003069. DOI: 10.1136/jitc-2021-003069.
    [63]
    CHEN WB, DING M, JI LY, et al. Bile acids promote the development of HCC by activating inflammasome[J]. Hepatol Commun, 2023, 7( 9): e0217. DOI: 10.1097/HC9.0000000000000217.
    [64]
    WEI Q, GUO PB, MU K, et al. Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome[J]. Lab Invest, 2015, 95( 7): 804- 816. DOI: 10.1038/labinvest.2015.63.
    [65]
    ZHANG Y, YANG H, SUN MF, et al. Alpinumisoflavone suppresses hepatocellular carcinoma cell growth and metastasis via NLRP3 inflammasome-mediated pyroptosis[J]. Pharmacol Rep, 2020, 72( 5): 1370- 1382. DOI: 10.1007/s43440-020-00064-8.
    [66]
    BHAT AA, THAPA R, AFZAL O, et al. The pyroptotic role of Caspase-3/GSDME signalling pathway among various cancer: A Review[J]. Int J Biol Macromol, 2023, 242( Pt 2): 124832. DOI: 10.1016/j.ijbiomac.2023.124832.
    [67]
    SHANGGUAN FG, ZHOU HF, MA NF, et al. A novel mechanism of cannabidiol in suppressing hepatocellular carcinoma by inducing GSDME dependent pyroptosis[J]. Front Cell Dev Biol, 2021, 9: 697832. DOI: 10.3389/fcell.2021.697832.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (43) PDF downloads(10) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return